Inexpensive generic prevents bleeding deaths after childbirth


An inexpensive generic drug has been found to prevent hemorrhaging in women after childbirth.

An inexpensive generic drug has been found to prevent hemorrhaging in women after childbirth.

The WOMAN Trial, involving more than 20,000 women in 21 countries, found that tranexamic acid “could save the lives of mothers who would otherwise bleed to death after childbirth,” according to the trial’s website. Tranexamic acid is an antifibrinolytic agent. It is on the WHO’s List of Essential Medicines.

In the United States, tranexamic acid is sold under the brand name Lysteda and Cyklokapron, with an indication for treating severe menstrual bleeding. The generic form of the drug costs about $2 per dose.

The study, conducted by the London School of Hygiene and Tropical Medicine, was published in the April 26 issue of The Lancet.

In the trial, death due to bleeding was reduced by about a third when tranexamic acid treatment was given within 3 hours. Tranexamic acid reduced the need for laparotomy to control bleeding by more than a third.

Next: Did this Attending remove the wrong fallopian tube?

There were no side effects observed from the drug for either mothers or babies.

“We now have important evidence that the early use of tranexamic acid can save women’s lives and ensure more children grow up with a mother,” the website stated.

Postpartum hemorrhage is the leading cause of maternal death worldwide.

In the randomized, double-blind, placebo-controlled trial, researchers recruited women aged 16 years and older with a clinical diagnosis of postpartum hemorrhage after a vaginal birth or cesarean delivery from 193 hospitals in 21 countries.

They randomly assigned women to receive either 1 (10 mg/ mL) dose of intravenous tranexamic acid or matching placebo, in addition to usual care. If bleeding continued after 30 minutes, or stopped and restarted within 24 hours of the first dose, a second dose of 1 g of tranexamic acid or placebo could be given.

The researchers found that death due to bleeding was significantly reduced in women given tranexamic acid (155 of 10,036 patients vs 191 of 9985 patients in the placebo group). In women given treatment within 3 hours of giving birth, death was reduced most significantly (89 in the tranexamic acid group vs 127 in the placebo group).

“Tranexamic acid reduces death due to bleeding in women with postpartum hemorrhage with no adverse effects,” the researchers wrote in The Lancet. “When used as a treatment for postpartum hemorrhage, tranexamic acid should be given as soon as possible after bleeding onset.”


1. WOMAN: reducing maternal deaths with tranexamic acid. The Lancet, Volume 389, Issue 10084, 2081. Accessed July 6, 2017.

Related Videos
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit:
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit:
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit:
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit:
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit:
raanan meyer, md
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit:
Related Content
© 2024 MJH Life Sciences

All rights reserved.